Stralem & Co. Inc. decreased its position in Danaher Co. (NYSE:DHR) by 13.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 212,195 shares of the conglomerate’s stock after selling 32,180 shares during the period. Danaher comprises 3.3% of Stralem & Co. Inc.’s investment portfolio, making the stock its 11th biggest position. Stralem & Co. Inc.’s holdings in Danaher were worth $19,696,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GQG Partners LLC purchased a new position in Danaher in the second quarter valued at $101,000. Zions Bancorporation increased its holdings in Danaher by 118.3% in the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after buying an additional 667 shares in the last quarter. Patten Group Inc. increased its holdings in Danaher by 262.3% in the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock valued at $114,000 after buying an additional 3,497 shares in the last quarter. Monetary Management Group Inc. increased its holdings in Danaher by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after buying an additional 150 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its holdings in Danaher by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after buying an additional 1,100 shares in the last quarter. 76.11% of the stock is owned by institutional investors.

DHR has been the subject of a number of research reports. Robert W. Baird reissued a “buy” rating and set a $99.00 target price on shares of Danaher in a research note on Friday, December 15th. Citigroup boosted their target price on shares of Danaher to $107.00 and gave the stock a “buy” rating in a research note on Friday, December 15th. Zacks Investment Research raised shares of Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a research note on Thursday, October 5th. Cowen reissued a “buy” rating and set a $90.00 target price on shares of Danaher in a research note on Wednesday, October 4th. Finally, Royal Bank of Canada reissued a “hold” rating and set a $96.00 target price on shares of Danaher in a research note on Thursday, January 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $94.91.

In related news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Donald J. Ehrlich sold 10,578 shares of the business’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total transaction of $960,693.96. Following the transaction, the director now owns 104,621 shares in the company, valued at $9,501,679.22. The disclosure for this sale can be found here. Insiders have sold 273,810 shares of company stock worth $25,218,813 over the last 90 days. 12.20% of the stock is currently owned by company insiders.

Danaher Co. (NYSE:DHR) traded up $0.45 on Wednesday, reaching $99.89. 1,550,000 shares of the company were exchanged, compared to its average volume of 2,300,000. The firm has a market capitalization of $69,480.00, a price-to-earnings ratio of 29.73, a PEG ratio of 2.15 and a beta of 1.03. Danaher Co. has a 52-week low of $78.97 and a 52-week high of $100.27. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.05. The firm had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. Danaher had a net margin of 13.36% and a return on equity of 11.29%. Danaher’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.87 earnings per share. equities analysts anticipate that Danaher Co. will post 3.99 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a dividend of $0.14 per share. The ex-dividend date is Thursday, December 28th. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. Danaher’s payout ratio is presently 16.67%.

COPYRIGHT VIOLATION WARNING: “Danaher Co. (DHR) Holdings Trimmed by Stralem & Co. Inc.” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/01/17/danaher-co-dhr-holdings-trimmed-by-stralem-co-inc.html.

About Danaher

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.